Tekmira: BIO CEO and Investor Conference (Tekmira Pharmaceuticals Corporation) - Feb 12, 2013 - "Administered to 23 patients at doses ranging from 0.15 mg/kg to 0.90 mg/kg with a total of 128 doses"; "One patient with a partial response at 0.60 mg/kg having received 23 doses over 8 months"; "One patient attained stable disease at 0.6 mg/kg having received 18 doses over 6 months"
P1 data • Oncology
|